Ranbaxy Laboratories and its Japanese parent Daiichi Sankyo's proposal to unveil a three- year plan for exploiting synergies in operations to enhance their generic and branded business worldwide has been delayed by two months.

Ranbaxy Chief Executive Officer and Managing Director Atul Sobti today said that the three-year plan, which was to be announced in January 2010 will be announced in March.

Also Read   Related Stories News Now - Ranbaxy Q4 PAT at Rs 262 cr - Ranbaxy stock price soars on US gains - Daiichi Sankyo to launch products in Mexico through Ranbaxy - Cipla retains top slot in domestic pharma market - Foreign pharma firms ride R&D tax relief revival hope - Daiichi swings to profit of $43 mn in Apr-Dec

Also Read   Related Stories News Now - Markets end flat - Turbulence ahead for airlines despite oil price drop - Weak rupee may bring cheer to NRIs, expats - LIC buys PSU stocks, sells pvt sector blue-chips in Q4 - Banks may lower deposit rates as inflation eases: Report More

The plan is aimed at enhancing value of both the companies with a focus on branded drugs, its back-end support, which includes research and development, and marketing.

"We are looking at better co-operation with Daiichi Sankyo as we are focussing on biologicals and vaccines also," Sobti said while adding that the company is also looking at exporting drugs to Japan from its facilities in India.

Market analysts had predicted that the synergy plan between the two companies could address issues such as accessing the Japanese market and leveraging on Ranbaxy's distribution network to launch its products in other markets.

The company added that its Batamandi facility at Paonta Sahib has got approval of Japanese healh regulator, PMDA.

Last year, both companies have entered into an pact under which Ranbaxy would market the branded products from Daiichi Sankyo's portfolio in the markets where the Japanese firm did not have presence.

The Gurgaon-based company had launched Evista, a drug used for treating osteoporosis, through its subsidiary in Romania from Daiichi Sankyo's portfolio. In Mexico, Ranbaxy has set-up a new marketing division to focus on Daiichi Sankyo's product.

Besides this, Ranbaxy has also introduced some of Daiichi Sankyo's product in India.

Daiichi Sankyo acquired majority stake in Ranbaxy Laboratories in 2008 for about Rs 22,000 crore.

New Ipad Application :Business Standard's all new IPad App Click here to download for free Other Stories      - Markets end flat - Turbulence ahead for airlines despite oil price drop - Weak rupee may bring cheer to NRIs, expats - LIC buys PSU stocks, sells pvt sector blue-chips in Q4 - Banks may lower deposit rates as inflation eases: Report

Tags : Daiichi | Ranbaxy Lab | synergy plan | pharma industry   Read Business news in  Advertisements -  Journey on, We are by Your Side. Click here to know more -  2 Lac Apartments, 1 Lac House / Plots. Click here -  Benefits Upto Rs. 2.36 Lakhs on the Fully Loaded TJet Petrol. -  The Best Seller is Also the No. 1 in Mileage. Click here -  Watch The Film Here. Click here to know more.. -  Leader in Passenger Car & Automobile Tyres. Click here -  1 billion in saving for Unilever without any tangles. -  A Brand New Server at a Price That Fits Your Budget. Click here -  Learn How One City is Running on FOOD SCRAPS. -  One Partnership Endless Possibilities. Click here to know more -  Helping doctors detect diseases earlier, saving costs & extending lives. -  36 Lakhs can get you a pool of Luxuries. Click here -  Which is the best plan for your daughter -  Check out the TRUE COLOURS of your Stocks, Now for FREE! -  One of the leading business schools in the world.Know More